Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
(NASDAQ: TBPH) Delayed: 16.97 +0.41 (2.48%)
Previous Close $16.56    52 Week High $38.92 
Open $16.70    52 Week Low $12.87 
Day High $17.10    P/E N/A 
Day Low $16.64    EPS $0.00 
Volume 676,267